GENFIT Highlights Long-Term Commercial Opportunity for its MASH Diagnostics Technology
Lille (France), Cambridge (Massachusetts, United States), September 9, 2026 - GENFIT Euronext:GNFT, a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today highlights the long-term commercial opportunity associated with NIS4® and…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.